

Attorney Docket No.: 5739.200-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#7  
JRP  
4/5/00

In re Application of: Weibel et al.

Application No.: 09/450,609

Group Art Unit: 1614

Filed: November 30, 1999

Examiner: J. Kim

For: New Pharmaceutical Composition And The Process For Its Preparation

## RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

This paper is being filed in response to the Office Action mailed March 22, 2000, which made a restriction requirement. Applicants were requested to elect one of the following designated groups:


Group I - claims 1, 2 and 6-16 drawn to pharmaceutical compositions, and

Group II - claims 3-5 and 17-19 drawn to methods of making pharmaceutical compositions.

In response to this requirement, Applicants hereby elect Group I. Applicants hereby reserve the right to file continuing applications directed to the nonelected subject matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,



Elias J. Lambiris, Reg. No. 33,728  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

Date: March 29, 2000

Attorney Docket No.: 5739.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Weibel et al.

Serial No.: 09/450,609

Group Art Unit: 1614

Filed: November 30, 1999

Examiner: J. Kim

For: New Pharmaceutical Composition And The Process For Its Preparation

**CERTIFICATE OF FACSIMILE TRANSMISSION**Assistant Commissioner for Patents  
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

**1. Response To Restriction Requirement**

was sent to the United States Patent Office by telefax to the attention of Examiner J. Kim, fax number (703) 305-3704.

Respectfully submitted,

Date: March 29, 2000

  
\_\_\_\_\_  
Carol McFarlane  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



OFFICIAL

# RESTRICTION ELECTION FACSIMILE TRANSMISSION

FAX RECEIVED

MAR 29 2000

DATE: March 29, 2000

GROUP 1600

FROM/ATTORNEY: Elias Lambiris, Esq., Reg. No. 33,728

FIRM: Novo Nordisk of North America, Inc.

PAGES, INCLUDING COVERSHEET: (3)

PHONE NUMBER: (202) 861-0123

TO EXAMINER: J. Kim

ART UNIT: 1614

SERIAL NUMBER: 09/450,609

FAX/TELECOPIER NUMBER: (703) 305-3704

**PLEASE NOTE: THIS FACSIMILE NUMBER IS TO BE USED ONLY  
FOR RESPONSES TO RESTRICTIONS.**

COMMENTS: \_\_\_\_\_

IF YOU HAVE NOT RECEIVED ALL THE PAGES OF THIS TRANSMISSION, PLEASE CONTACT THE ATTORNEY AT THE  
TELEPHONE NUMBER LISTED ABOVE.

IN COMPLIANCE WITH 1096 OG 30, THE FILING DATE ACCORDED EACH OFFICIAL FAX TRANSMISSION WILL BE  
DETERMINED BY THE FAX MACHINE DATE STAMP FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT  
DATE IS A SATURDAY, SUNDAY, OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE  
OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAIN(S) INFORMATION FROM THE UNITED  
STATES PATENT AND TRADEMARK OFFICE WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THIS  
INFORMATION IS FOR THE USE OF THE INDIVIDUAL OR FIRM NAMED ON THIS SHEET. IF YOU ARE NOT THE  
INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR THE  
TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. THE  
DOCUMENTS SHOULD BE RETURNED TO THE PATENT AND TRADEMARK OFFICE IMMEDIATELY. IF THIS FACSIMILE IS  
RECEIVED IN ERROR, PLEASE NOTIFY THE ATTORNEY LISTED HEREON IMMEDIATELY.